Daina Technology and the Zhejiang Central Laboratory have jointly established an AI‑driven closed-loop CRO platform for traditional Chinese medicine.

On June 26, the inaugural World Conference on Artificial Intelligence in Traditional Chinese Medicine was grandly held in Hangzhou. During the event, Beijing Dyna Experimental Technology Co., Ltd. and the Central Zhejiang Laboratory (Jinhua Research Institute of Zhejiang University of Traditional Chinese Medicine) formally signed an agreement to jointly establish the world’s first AI‑driven closed-loop CRO platform for traditional Chinese medicine. Anchored by a comprehensive workflow—“literature review—prescription generation—active ingredient extraction—formula optimization—organoid validation—high‑quality data generation and feedback”—the platform achieves end-to-end AI‑autonomization of TCM research and development, marking the entry of TCM modernization into a new era defined by “data‑driven approaches and intelligent decision‑making.”

(Dai Haipeng, Chairman of Daina Technology, and the Vice President of Zhejiang University of Traditional Chinese Medicine and Director of the Jinhua Research Institute) Wen Chengping)

Traditional Chinese medicine research and development has long relied on the inheritance of empirical knowledge and manual trial-and-error. The expertise of renowned veteran TCM practitioners, ancient prescriptions from classical texts, and intangible cultural heritage items have been difficult to systematically mine, while validation of pharmacological mechanisms has lacked standardized data support. The AI CRO platform for traditional Chinese medicine, jointly developed by Daina Technology and the Jinhua Research Institute of Zhejiang University of Traditional Chinese Medicine, is the first to fully integrate an AI + Lights-out Laboratories technological framework into the TCM domain—spanning intelligent analysis of vast amounts of literature, AI‑driven autonomous generation of prescriptions, precise extraction of active ingredients, pharmacological efficacy verification at the organoid level, continuous optimization through a closed‑loop data system, and end-to-end services for commercial translation—thereby establishing an innovative infrastructure that fuses “classical wisdom with modern technology.”

The inaugural World Conference on Artificial Intelligence in Traditional Chinese Medicine focuses on seven core topics, Daina Technology. The AI‑powered TCM CRO platform aligns seamlessly with each of these key dimensions: At the level of “AI Breaking Barriers to Traditional Knowledge,” the platform systematically mines the expertise of renowned senior TCM practitioners and ancient formulae, transforming millennia‑old wisdom into computable, reusable digital assets; at the level of “Accelerating Scientific Advancement,” AI‑driven clinical big‑data analytics and validation of therapeutic mechanisms provide evidence‑based support for the modernization of TCM; at the level of “Empowering Diagnosis, Treatment, and R&D,” intelligent capabilities—including syndrome differentiation assistance, prediction of pharmacological efficacy and toxicity, and quality control—span the entire new‑drug discovery cycle; at the level of “Smart Manufacturing,” smart pharmaceutical plants and AI‑enabled quality‑control systems throughout the entire process of herb cultivation and processing ensure consistent quality from field to factory floor; at the level of “Personalized Health Management,” an AI‑based health‑management assistant tailored to individual constitutions, coupled with wearable devices, brings the TCM principle of “preventing disease” directly to the individual; at the level of “Global Standard‑Setting,” the platform’s standardized datasets and algorithmic models contribute a Chinese approach to establishing international AI standards for TCM; and at the level of “International Promotion and Cultural Exchange,” a multidimensional output integrating TCM, AI, and foreign languages helps facilitate the practical implementation of TCM in countries along the Belt and Road.

Centering on AI4S‑driven R&D, application, and commercialization in the field of traditional Chinese medicine (TCM), Daina Technology will pursue six core business lines: intelligent formulation optimization for TCM, leveraging AI algorithms to reengineer the “chief–minister–assistant–guide” compatibility framework; development and industrialization of TCM organ‑on‑a‑chip platforms, using biomimetic technologies to replace animal testing and accelerate efficacy validation; construction and operation of standardized datasets for TCM formulas, transforming time‑tested expertise into data‑driven assets; intelligent screening and R&D of bioactive compounds in Han‑style TCM, precisely identifying active molecules from vast libraries of natural products; translation of related technological advances into practical applications, bridging the “last mile” between laboratory research and industrial deployment; and provision of technical consulting, services, product sales, and related ancillary businesses, thereby establishing a sustainable commercial ecosystem.

Traditional Chinese medicine is a treasured gem of Chinese civilization, yet its modernization has long been hampered by the challenges of “difficult inheritance, difficult validation, and difficult standardization.” Daina Technology is entering this strategic field with AI + Lights-out Laboratories technology, which not only expands the company’s technological boundaries but also represents an active response to the national strategy of “Healthy China.” The establishment of the world’s first AI‑closed‑loop TCM CRO platform will enable AI to decipher the wisdom embedded in ancient texts, ensure that the experience of veteran TCM practitioners is passed down through data, and breathe new life into millennia‑old prescriptions in the age of intelligence.